OGD 202

Drug Profile

OGD 202

Alternative Names: Anti-GD2-RLI - OGD2 Pharma; ICK IL-15 - OGD2 Pharma; OGD202

Latest Information Update: 04 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OGD2 Pharma
  • Class Cytokines; Immunoconjugates; Interleukins
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 28 Jun 2016 Preclinical trials in Cancer in France (Parenteral)
  • 21 Jun 2016 OGD2 Pharma and Green Cross LabCell agree on the development of Monoclonal antibodies against OAcGD2 for the treatment of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top